Failure (biologic function)
Allakos Announces Discontinuation of AK006 Program and 75% Layoffs Following Clinical Trial Failures
Allakos, AK006, clinical trial failure, layoffs, biotech, chronic spontaneous urticaria, atopic dermatitis
Allakos Discontinues AK006 Development, Cuts 75% of Workforce Amid Strategic Restructuring
Allakos, AK006, workforce reduction, strategic alternatives, Phase 1 trial failure, chronic spontaneous urticaria (CSU), biotechnology, restructuring costs.
Denali Therapeutics Faces Another Setback in ALS Treatment Development
Denali Therapeutics, ALS, Phase II/III trial, HEALEY ALS Platform trial, DNL343, treatment failure
Roche’s Parkinson’s Drug Fails Second Mid-Stage Trial, Yet Shows Promising Trends
Roche, Parkinson’s disease, prasinezumab, clinical trial failure, promising trends, further exploration
Acelyrin Reassesses Flagship Immunology Asset Izokibep Following Multiple Clinical Trial Setbacks
Acelyrin, Izokibep, Clinical Trial Failure, Immunology, Hidradenitis Suppurativa, Psoriatic Arthritis, Biotech IPO
GSK Terminates Development of HBV Therapeutic Vaccine Due to Efficacy Failure
GSK, HBV, therapeutic vaccine, efficacy failure, clinical trial termination
PTC Therapeutics Sells Priority Review Voucher for $150M Following Phase 2 ALS Trial Failure
PTC Therapeutics, ALS, Phase 2 trial failure, priority review voucher, $150M sale
Outlook Therapeutics Stock Crashes Following Clinical Trial Failure for Wet AMD Therapy
Outlook Therapeutics, OTLK, stock price, clinical trial failure, wet AMD therapy, ONS-5010, FDA filing
Alector Cuts 17% of Workforce Following Failure of AbbVie-Partnered Alzheimer’s Drug in Phase 2 Trial
Alector, layoffs, AbbVie, Alzheimer’s disease, phase 2 trial failure, biotech industry
Cassava Sciences’ Alzheimer’s Drug Fails in Clinical Trial, Stock Plummets
Cassava Sciences, Alzheimer’s disease, clinical trial failure, ReThink-ALZ study, stock decline